Literature DB >> 15703466

A case-control analysis of intra-arterial urokinase thrombolysis in acute cardioembolic stroke.

Takeshi Inoue1, Kazumi Kimura, Kazuo Minematsu, Takenori Yamaguchi.   

Abstract

BACKGROUND: Intra-arterial urokinase (IA-UK) thrombolysis is frequently given in Japan to selected patients with acute cerebral artery occlusion. However, it is not clear whether or not IA-UK thrombolysis has an efficacy for acute stroke patients. The purpose of this study was to assess the effects of IA-UK thrombolysis in acute cardioembolic stroke patients, by performing a case-control analysis using data from Japan's Multicenter Stroke Investigator's Collaboration (J-MUSIC).
METHODS: 16,922 acute ischemic stroke patients were enrolled into J-MUSIC. From these patients, we selected 91 patients (UK group) who met the following criteria: treatment with IA-UK; 20-75 years of age; cardioembolic stroke; presenting with a carotid stroke; admission within 4.5 h of symptom onset, and a National Institutes of Health Stroke Scale (NIHSS) score of 5-22 points on admission. A control group of 182 patients without IA-UK treatment and matched to the NIHSS score, gender, and age was chosen. We compared the modified Rankin scale (mRS) score at discharge and the mortality between the 2 groups.
RESULTS: In both groups, the mean age was 65 +/- 8 years, and the median NIHSS score was 14. The mean interval between symptom onset and UK administration was 3.4 +/- 1.3 h, and the IA-UK dose was 392,000 +/- 200,000 units. The mRS score at discharge was lower in the UK group than in the control group (mean, SD, median; 2.8, 2.9, 2 in UK group vs. 3.3, 1.8, 4, in the control, respectively p = 0.031). A favorable outcome (mRS of 0-2) was more frequently observed in the UK group (50.5%) than in the control group (34.1%, p = 0.0124). No difference in the mortality rate was seen between the UK group (11.0%) and the control group (13.3%). As well, there was no difference in the length of hospital stay between the UK group (46 +/- 41 days, mean +/- SD) and the control group (42 +/- 42 days, mean +/- SD).
CONCLUSIONS: IA-UK thrombolytic therapy may improve the outcome in hyperacute cardioembolic stroke patients. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703466     DOI: 10.1159/000083887

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

1.  Multimodal reperfusion therapy for large hemispheric infarcts in octogenarians: is good outcome a realistic goal?

Authors:  D Arkadir; R Eichel; J M Gomori; T Ben Hur; J E Cohen; R R Leker
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-02       Impact factor: 3.825

Review 2.  Developing practice recommendations for endovascular revascularization for acute ischemic stroke.

Authors:  Marc A Lazzaro; Roberta L Novakovic; Andrei V Alexandrov; Ziad Darkhabani; Randall C Edgell; Joey English; Donald Frei; Dara G Jamieson; Vallabh Janardhan; Nazli Janjua; Rashid M Janjua; Irene Katzan; Pooja Khatri; Jawad F Kirmani; David S Liebeskind; Italo Linfante; Thanh N Nguyen; Jeffrey L Saver; Lori Shutter; Andrew Xavier; Dileep Yavagal; Osama O Zaidat
Journal:  Neurology       Date:  2012-09-25       Impact factor: 9.910

3.  Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke.

Authors:  R M Sugg; E A Noser; H M Shaltoni; N R Gonzales; M S Campbell; R Weir; E D Cacayorin; J C Grotta
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

4.  Thrombolysis based on magnetically-controlled surface-functionalized Fe3O4 nanoparticle.

Authors:  Ming Chang; Yu-Hao Lin; Jacque Lynn Gabayno; Qian Li; Xiaojun Liu
Journal:  Bioengineered       Date:  2016-09-30       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.